Expanding treatment options by selectively targeting the cytokine storm with ruxolitinib in primary hemophagocytic lymphohistiocytosis. | Haematologica;109(2): 374-375, 2024 Feb 01. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

Expanding treatment options by selectively targeting the cytokine storm with ruxolitinib in primary hemophagocytic lymphohistiocytosis.

Van Laar, Jan A M.

Affiliation

Van Laar JAM; Section of Clinical Immunology, Department of Internal Medicine and Immunology, Erasmus University Medical Center Rotterdam, Rotterdam. j.vanlaar@erasmusmc.nl.

Haematologica ; 109(2): 374-375, 2024 Feb 01.

Article in En | MEDLINE | ID: mdl-37675517

Subject(s)

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrazoles / Lymphohistiocytosis, Hemophagocytic / Cytokine Release Syndrome Limits: Humans Language: En Journal: Haematologica Year: 2024 Document type: Article

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrazoles / Lymphohistiocytosis, Hemophagocytic / Cytokine Release Syndrome Limits: Humans Language: En Journal: Haematologica Year: 2024 Document type: Article